Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Amotiv Limited

AOV
Current price
5.22 CAD +0.08 CAD (+1.56%)
Last closed 5.15 CAD
ISIN CA4990531069
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange Toronto Exchange
Capitalization 581 851 909 CAD
Yield for 12 month +0.77 %
1Y
3Y
5Y
10Y
15Y
AOV
21.11.2021 - 28.11.2021

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada. Address: 3400 de Maisonneuve Boulevard West, Montreal, QC, Canada, H3Z 3B8

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

10.1 CAD

P/E ratio

Dividend Yield

Current Year

+331 056 637 CAD

Last Year

+296 119 060 CAD

Current Quarter

+87 358 063 CAD

Last Quarter

+74 843 036 CAD

Current Year

+153 981 145 CAD

Last Year

+139 263 101 CAD

Current Quarter

+42 062 074 CAD

Last Quarter

+34 512 910 CAD

Key Figures AOV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 50 218 479 CAD
Operating Margin TTM 3.07 %
PE Ratio
Return On Assets TTM 0.21 %
PEG Ratio 2856.67
Return On Equity TTM -2.21 %
Wall Street Target Price 10.1 CAD
Revenue TTM 335 098 542 CAD
Book Value 7.6 CAD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 4.9 %
Dividend Yield
Gross Profit TTM 139 263 101 CAD
Earnings per share -0.16 CAD
Diluted Eps TTM -0.16 CAD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY 800 %
Profit Margin -5.25 %

Dividend Analytics AOV

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History AOV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation AOV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 263.1579
Enterprise Value Revenue 1.4491
Price Sales TTM 1.7571
Enterprise Value EBITDA 11.629
Price Book MRQ 0.7721

Financials AOV

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators AOV

For 52 weeks

5.11 CAD 6.28 CAD
50 Day MA 5.86 CAD
Shares Short Prior Month 3 138 062
200 Day MA 5.41 CAD
Short Ratio 49.42
Shares Short 3 123 744
Short Percent 2.52 %